CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash Flows From Operating Activities:
Net (Loss)	$ (16,882,001)	$ (14,748,618)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization	384,835	583,501
Share Based Compensation - Non-employee	158,667
Share Based Compensation- Employees	5,874,769	7,794,690
Loss on Disposal of Assets	4,084	7,340
Loss (gain) on Sale of Investments Available for Sale	704,695	26,820
Changes in Assets and Liabilities:
(Increase) Decrease in Accounts Receivable	(149,429)	(2,984,463)
(Increase) in Inventory	(2,391,191)	(3,888,489)
(Increase) in Other Assets	224,635	(1,376,042)
Increase (Decrease) in Accounts Payable	(1,669,651)	(598,427)
Increase (Decrease) in Other Liabilities	(863,034)	(179,856)
Increase (decrease) Deferred License Revenue	(1,494,360)	(1,445,058)
Increase (decrease) in deferred drug license revenue	(204,543)	3,818,184
Changes in Assets and Liabilities	(6,547,573)	(6,654,151)
Cash (Used In) Operating Activities	(16,302,524)	(12,990,418)
Cash Flows From Investing Activities:
Purchase of Investments Available for Sale	(34,235,347)	(23,158,809)
Sale of Investments Available for Sale	40,122,266	24,491,678
Purchase of Equipment	(706,346)	(328,322)
Proceeds on Sale of Assets	450	1,000
Cash Provided by Investing Activities	5,181,023	1,005,547
Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Shares and Purchase Warrants	116,105	80,161
Restricted Stock Retained in Satisfaction of Tax Liabilities	(2,287,231)
Cash Provided By (Used In) Financing Activities	(2,171,126)	80,161
Effects of exchange rate changes	(44)	(18)
(Decrease) In Cash	(13,292,671)	(11,904,728)
Cash At Beginning Of Period	17,180,594	31,198,182
Cash At End Of Period	$ 3,887,923	19,293,454
Supplemental Cash Flow Information:
Income Taxes Paid		$ 404,527